4 Healthcare Stock Stories For Monday Investment Wellness

Eli Lilly and Co. (NYSE:LLY): Closing price $51.11

On Monday, Lilly said that the Centers for Medicare & Medicaid Services has released a draft decision proposing Coverage with Evidence Development for the utilization of beta-amyloid positron emission tomography imaging agents, which are used to evaluate patients with cognitive impairment from Alzheimer’s Disease and other causes of cognitive decline. An Amyvid (Florbetapir F 18 Injection) beta-amyloid scan is meant to be used in adults with thinking or memory problems, who are being assessed for Alzheimer’s Disease or other causes of these symptoms. A positive Amyvid scan does not indicate Alzheimer’s Disease or other thinking or memory disorders, as Amyvid is not cleared to predict the development of dementia or other future brain conditions, or for monitoring the effectiveness of treatments.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

LLY

Response Genetics, Inc. (NASDAQ:RGDX): Closing price $1.63

Response Genetics announced on Monday that it has recently signed a provider contract with Blue Cross and Blue Shield of Illinois. The insurer currently has 7.4 million members, most of whom reside in the State of Illinois. With this agreement, oncologists and pathologists connected with this health plan now can more easily offer Response Genetics’ suite of molecular predictive testing for their patients struggling with lung, colon, gastric, and melanoma cancers.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

RGDX

BioDelivery Sciences International (NASDAQ:BDSI): Closing price $4.71

The company said Monday that it has obtained a $20-million senior secured loan from an affiliate of MidCap Financial, LLC. The proceeds of the loan bolsters the cash position as BDSI moves towards the submission of a new drug application for Bunavail and the completion of the two Phase 3 clinical studies for BEMA Buprenorphine for chronic pain, the second of which would result in milestone payments to BDSI from its commercial partner, Endo Health Solutions.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

BDSI

Amarin Corp. (NASDAQ:AMRN): Closing price $6.17

On Monday, Amarin reported that it is offering to sell 21.7 million American Depositary Shares in an underwritten public offering. Also, the corporation has granted the underwriters a 30-day option through which to buy an additional 3,255,000 ADSs. Further details in connection to this transaction should be made available in a Current Report on Form 8-K to be filed by BDSI with the Securities and Exchange Commission.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

AMRN

Investing Insights: Is Chevron or Johnson & Johnson’s Dividend Superior?